Trials / Completed
CompletedNCT00401544
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients with non-myeloid malignancies who were receiving multicycle chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | darbepoetin alfa | Darbepoetin alfa administered by subcutaneous injection. |
| DRUG | IV iron dextran | Administered by intravenous (IV) injection. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-12-01
- Completion
- 2008-03-01
- First posted
- 2006-11-20
- Last updated
- 2014-01-29
- Results posted
- 2014-01-29
Source: ClinicalTrials.gov record NCT00401544. Inclusion in this directory is not an endorsement.